Lipid Nanoparticle Composition for Stable Intracellular RNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lipid nanoparticle formulations face challenges in protecting nucleic acids from degradation in plasma, facilitating intracellular delivery, and ensuring adequate therapeutic index without unacceptable toxicity.
Innovation Solution
Lipid nanoparticles comprising 47 to 48 mol percent of a cationic lipid, a neutral lipid, cholesterol, and a pegylated polymer conjugated lipid, with specific alkyl chain and mean value ranges, encapsulating therapeutic agents like mRNA or antisense oligonucleotides, enhance stability and delivery efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If free RNA is used for therapeutic delivery, then the therapeutic agent can reach the intracellular compartment, but the RNA is susceptible to nuclease digestion in plasma
Solution Approach 1:
Lipid nanoparticles serve as an intermediary carrier system that protects therapeutic RNA from plasma nucleases while facilitating intracellular delivery. The lipid formulation creates a protective interface between the vulnerable RNA and the hostile plasma environment, enabling both stability and delivery functionality.
2Productivity
If cationic lipid formulations are used to protect nucleic acids and facilitate cellular uptake, then delivery efficiency improves, but toxicity increases
Solution Approach 1:
The invention optimizes the cationic lipid content to a specific range (47-48 mol percent) and adjusts the effective pKa to 6.0-6.5, representing precise parameter changes that maximize delivery efficiency while minimizing toxicity. This narrow optimization window balances the competing requirements of cellular uptake and safety.
Solution Approach 2:
The lipid formulation creates different functional zones within the nanoparticle structure, with cationic lipids concentrated at the surface for cellular interaction and neutral/steroid lipids providing structural integrity and protection, thereby localizing toxic effects while maintaining delivery functionality.
3Productivity
If higher cationic lipid concentration is used in lipid nanoparticles, then encapsulation efficiency and in vivo activity increase, but the formulation complexity and optimization requirements increase
Solution Approach 1:
The invention specifies precise parameter ranges (47-48 mol percent cationic lipid, effective pKa 6.0-6.5) that simplify formulation development by providing clear target values, reducing the complexity of optimization while achieving high encapsulation efficiency and in vivo activity.
Data Source
Figure 1A~1B
AI summary
Improved formulations of lipid nanoparticles are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent and methods for their preparation are also provided.